aBLA Filing Intelligence & Biosimilar Opportunity

Zynlonta

Loncastuximab Tesirine-Lpyl

Anticancer

Injection Injectable

Approval Date

23-Apr-21

Data Exclusivity Expiry

23-Apr-25

Market Exclusivity Expiry

23-Apr-33

Commercial snapshot

Market performance & projections

Revenue ($M)

102

CAGR (%)

0.2996

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

103

2027

139

2028

217

2029

291

2030

333

2031

358

2032

375

Molecule profile

Details & specifications

Molecule

Loncastuximab Tesirine-Lpyl

Innovator

ADC THERAPEUTICS AMERICA, INC.

Dosage Form

Injection Injectable

Strength

10 mg

Therapeutic Category

Anticancer

Usage

To treat certain types of relapsed or refractory large B-cell lymphoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.